New drug combo PrimeC shows promise in slowing ALS

NCT ID NCT05357950

Completed Disease control Sponsor: NeuroSense Therapeutics Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase IIb trial tested PrimeC, a combination of two common drugs (ciprofloxacin and celecoxib), in 69 people with ALS. Participants took PrimeC or a placebo for 6 months, followed by a 12-month open-label extension where everyone received PrimeC. The study measured safety, side effects, and how well the drug slowed disease progression using standard ALS rating scales and breathing tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PrimeC (a combination of ciprofloxacin and celecoxib)
What this could lead to: If successful, PrimeC could slow the progression of ALS and improve quality of life for patients.
What could go wrong: This is a small, early-phase (IIb) trial with only 69 participants. Results may not be conclusive, and the drug may not show significant benefit over placebo. Side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

A.O.U. Citta della Salute e della Scienza di Torino

Torino, Italy
IRCCS Istituti clinici Maugeri

Milan, Italy
Lawson Health Research Institute

London, Ontario, Canada
Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.